Orthocell Ltd ( (AU:OCC) ) has provided an update.
Orthocell Limited has announced the successful launch and first sales of its dental guided bone and tissue regeneration product, Striate+™, in Germany, Austria, and Switzerland, marking a significant step in its European market expansion. This move, facilitated by their distribution partner BioHorizons, is expected to rapidly increase sales and revenue, with the company targeting a 20% share of the over A$1 billion global market. The product’s strong performance, backed by a 98.6% success rate in clinical studies, and positive feedback from dental surgeons, positions Orthocell for further growth, particularly with anticipated regulatory approval in Brazil within three months.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company focused on developing products for the repair of bone and soft tissue injuries. Their portfolio includes the CelGro™ platform of collagen medical devices, which aid in tissue reconstruction and healing in dental and orthopedic applications. Striate+™, a product for dental guided bone regeneration, is distributed globally by BioHorizons Implant Systems Inc. Orthocell is also advancing other products like Remplir™ for nerve reconstruction and SmrtGraft™ for tendon repair.
YTD Price Performance: 14.71%
Average Trading Volume: 1,575,652
Technical Sentiment Signal: Sell
Current Market Cap: A$355.7M
For an in-depth examination of OCC stock, go to TipRanks’ Stock Analysis page.